

ORTHOPEDIC FOUNDATION FOR ANIMALS, INC.

LORELEI THE SINGING SIREN
registered name

ALASKAN MALAMUTE
breed

film/test/lab #

tattoo/microchip/DNA profile

2225357
application number

05/26/2021
date of report

RESULTS:

Based upon the exam dated 05/10/2021, this dog has been found to be free of observable inherited eye disease and has been issued an Eye Certification Registry Number which is valid for one year from the time of the exam.

owner
KRISTI HEFFINGTON
10211 OCEAN GTWY
EASTON MD 21601

WS59851309
registration no.

F
sex

02/12/2018
date of birth

38
age at evaluation in months



A Not-For-Profit Organization

AM-EYE880/38F-NOPI

O.F.A. NUMBER

This number issued with the right to correct or revoke by the Orthopedic Foundation for Animals.

NORMAL

OFA eCert



Verify certificate with QR scan

G.G.KELLER, D.V.M., M.S., DACVR
CHIEF OF VETERINARY SERVICES

www.ofa.org

ORTHOPEDIC FOUNDATION FOR ANIMALS, INC.

LORELEI THE SINGING SIREN
registered name

ALASKAN MALAMUTE
breed

212767
film/test/lab #

tattoo/microchip/DNA profile

2225357
application number

03/15/2021
date of report

RESULTS:

POLYNEUROPATHY: CLEAR

WS59851309
registration no.

F
sex

02/12/2018
date of birth

36
age at evaluation in months



A Not-For-Profit Organization

AM-PN206/36F-NOPI
O.F.A. NUMBER

*This number issued with the right to correct or
revoke by the Orthopedic Foundation for Animals.*

CLEAR

owner
KRISTI HEFFINGTON
10211 OCEAN GTWY
EASTON MD 21601

OFA eCert



Verify certificate
with QR scan

G.G.KELLER, D.V.M., M.S., DACVR
CHIEF OF VETERINARY SERVICES

www.ofa.org

Laboratory Report

Laboratory #:	212767	Call Name:	Lorelei
Order #:	97218	Registered Name:	Lorelei The Singing Siren
Ordered:	Jan. 10, 2021	Breed:	Alaskan Malamute
Received:	Feb. 25, 2021	Sex:	Female
Reported:	March 3, 2021	DOB:	Feb. 2018
		Registration #:	WS59851309

Results:

Disease	Gene	Genotype	Interpretation
Alaskan Malamute Polyneuropathy	<i>NDRG1</i>	WT/WT	Normal (clear)


WT, wild type (normal); M, mutant; Y, Y chromosome (male)

Interpretation:

Molecular genetic analysis was performed for a specific mutation reported to be associated with Alaskan Malamute Polyneuropathy in dogs. We identified two normal copies of the DNA sequences in the *NDRG1* gene tested. Thus, this dog is not at an increased risk for Alaskan Malamute Polyneuropathy.

Recommendations:

No mutations were identified. Thus, this dog is not at an increased risk for the disease caused by or associated with the mutation tested. Because this dog is "clear" of this mutation, this dog will only pass the normal gene on to its offspring. Normal results do not exclude inherited mutations not tested in this gene or other genes that may cause medical problems or may be passed on to offspring. Paw Print Genetics® has genetic counseling available to you at no additional charge to answer any questions about these test results, their implications and potential outcomes in breeding this dog.



Blake C Ballif, PhD
Laboratory & Scientific Director



Casey R Carl, DVM
Associate Medical Director

Normal results do not exclude inherited mutations not tested in these or other genes that may cause medical problems or may be passed on to offspring. These tests were developed and their performance determined by Paw Print Genetics®. This laboratory has established and verified the tests' accuracy and precision. Because all tests performed are DNA-based, rare genomic variations may interfere with the performance of some tests producing false results. If you think these results are in error, please contact the laboratory immediately for further evaluation. In the event of a valid dispute of results claim, Paw Print Genetics will do its best to resolve such a claim to the customer's satisfaction. If no resolution is possible after investigation by Paw Print Genetics with the cooperation of the customer, the extent of the customer's sole remedy is a refund of the fee paid. In no event shall Paw Print Genetics be liable for indirect, consequential or incidental damages of any kind. Any claim must be asserted within 60 days of the report of the test results.